Peer-Support Groups Were Right, Guidelines Were Wrong: Dr. Mark Horowitz on Tapering Off Antidepressants
In an interview with MIA, Dr. Horowitz discusses his recent article on why tapering off antidepressants can take months or even years.
A new article in Lancet Psychiatry finds that slower tapering of SSRIs is better for preventing antidepressant withdrawal effects.
Meta-analysis of antidepressant tapering finds CBT and MBCT can aid in tapering, but limited studies met inclusion criteria.
The researchers found that although antidepressants had a slight short-term effect on reducing the likelihood of depression diagnosis, there was no long-term improvement, nor any improvement in motor functioning.
In the interest of the patients who are currently experiencing withdrawal reactions and the many more who will suffer withdrawal effects in the future, we need to end this “war.” Academic psychiatry must address these problems and conduct thorough research on withdrawal reactions.
The patient experiencing the pain of withdrawal believed that they would feel better when they stopped taking their antidepressants. After all, they’re under the care of a board-certified medical professional who has vowed to do no harm. But despite those reassurances, they find themselves in a world of hurt.
Researchers question the overstated results of a large antidepressant meta-analysis and point to cultural pressures to turn to these drugs for a quick fix.
Antidepressant withdrawal is no longer an unknown disorder since knowledge on this topic has grown enough to be translated into practice. As proposed by George Engel in 1977, medical doctors, including psychiatrists, can observe and listen to their patients and develop a program to treat withdrawal and restore health.
Researchers explore the effects of augmented treatment at various points in interpersonal psychotherapy for adolescents diagnosed with depression, highlighting previously unidentified critical decision points (i.e., relatively early in the treatment sequence).
Biologists found that exposure to antidepressants suppresses important survival behaviors in zebrafish, an effect that persisted across three generations and was found to be more severe for males.
Bipolar drug therapy is a balancing act of benefits vs. harms. Odds of attributable benefit cluster in a 15-25% band, so 75%-85% don’t see substantial benefit. Stated differently, if five people take a bipolar drug, only one is likely to see substantial improvement due to it, but all five will have side effects.
One of the criticisms of our systematic review was that it failed to include five randomised control trials. Here we will show how groundless this is, and thus gain insight into how shadowy and ethically suspect antidepressant withdrawal research can get when viewed up close.
Researchers challenge the recommendation of starting two antidepressants simultaneously to increase preventative effects against suicide.
In parts of Wales in the UK, one in six adults takes antidepressants and support for anyone struggling with dependence or withdrawal issues is patchy and inconsistent. To help draw attention to these issues, an awareness day was arranged for the Welsh Government and here we provide video of the presentations made at the Senedd in Cardiff, Wales.
An international group of researchers, including several with financial ties to manufacturers of antidepressants, explore possible explanations for why long-term users of antidepressants become chronically depressed.
A new as-yet-unpublished trial of duloxetine (Cymbalta) for fibromyalgia has presented more evidence of suicidal events in teens.
Psychiatrist and psychologist outline pharmacological and psychotherapeutic strategies for discontinuing antidepressants.
Much of what Allen Frances says is sensible, but it would be more convincing if he would lay the responsibility for the present state of affairs squarely where it belongs: on psychiatry. I suggest, in all sincerity, that Dr. Frances abandon his attempt to absolve psychiatry from blame, and that he join the anti-psychiatry movement.
A new study, published in Psychological Medicine, found evidence for a specific type of publication bias distorting the evidence about antidepressant efficacy.
New research suggests that clinicians should exercise caution prescribing SNRIs as first-line treatment for mood and anxiety disorders.
Prominent researchers conduct a review of antidepressant withdrawal incidence, duration, and severity. Results lead to call for new clinical guidelines.
Reanalysis of the original primary outcome measure in the STAR*D study suggests STAR*D findings inflate improvement on antidepressant medication and exclusion criteria in conventional clinical trials results in overestimation of antidepressant efficacy.
Findings point to the role of withdrawal symptoms and prescriber practices in long-term antidepressant use.
A new study finds that more than a third of Americans are taking prescription drugs that can cause depressive symptoms as a side-effect.
A new article in BMJ Evidence-Based Medicine addresses common misinterpretations of the efficacy research on antidepressants.